Press Releases

Artificial DNA can control release of active ingredients from drugs

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was once a pharmacologist's dream is now much closer to...

SpringWorks and GSK sign clinical trial collaboration agreement

SpringWorks Therapeutics has signed an agreement to assess its nirogacestat in combination with GlaxoSmithKline’s (GSK) belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma. Under the clinical trial collaboration agreement, GSK will sponsor and conduct an adaptive Phase...

Velabs Therapeutics Announces 3 Million Series B Financing to Advance its Functional Antibody Screening Programme

Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional...

AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the Genetic Abnormality

AbbVie , a research-based global biopharmaceutical company announced that the U.S. FDA  has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluating venetoclax (VENCLEXTA® OR VENCLYXTO®) for the investigational treatment of relapsed/refractory multiple myeloma....

Parexel Strengthens Risk-Based Monitoring Offering with CluePoints’ New Advanced Statistical Capabilities

Parexel, a leading provider of Clinical, Consulting and Commercial solutions to accelerate the development of innovative new therapies to improve the world’s health. Announced  its strategic collaboration with CluePoints, an industry-leading provider of Risk-Based Study Execution...

Pharmacosmos A/S announces publication of positive results from the FERWON-NEPHRO study

Pharmacosmos A/S announces publication of positive results from the FERWON-NEPHRO study and the pre-specified pooled safety analyses of the FERWON-NEPHRO and FERWON-IDA studies at the 56th ERA-EDTA congress in Budapest, Hungary. FERWON-NEPHRO is the second trial...

Quanticate Expands Presence in North America with New Toronto Office

Quanticate, a leading global data-focused clinical research organisation(CRO), has announced plans to expand its presence in North America with the opening of a new office in Toronto. Quanticate will deliver statistical consultancy, programming, data management, pharmacovigilance,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read